Takrolimus Ölçüm Yöntemleri
Synopsis
In this chapter of "Güncel Biyokimya Çalışmaları II", authored by Specialist Dr. Andaç Uzdoğan, therapeutic drug monitoring methods for tacrolimus—a widely used immunosuppressant in organ transplantation—are examined in detail. Derived from Streptomyces tsukubaensis and inhibiting T-cell activation, this macrolide-class drug can lead to toxic effects such as nephrotoxicity and neurotoxicity at high doses, and acute organ rejection at low doses due to its narrow therapeutic window. Consequently, drug level measurements routinely performed on EDTA whole blood carry vital importance in the clinical monitoring of patients. The text comparatively addresses immunological methods used to determine tacrolimus levels—such as EMIT, ACMIA, CMIA, and ECLIA—alongside the chromatographic LC-MS/MS technique. While immunological methods are noted for carrying the risk of falsely elevated or decreased results due to metabolite cross-reactions and interferences, the LC-MS/MS method, offering high sensitivity and specificity, is highlighted as the recommended standard for preventing interference. Furthermore, the financial budget and trained personnel requirements of the method, along with preanalytical factors and drug interactions affecting tacrolimus measurements and pharmacokinetics, are elaborated.
References
Brunet M, van Gelder T, Asberg A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit 2019;41(3):261-307.
Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK 506. Immunol Today 1992;13:136-142.
Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantaion. Drugs 1997;54:925-975.
Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK-506): molecular and cellular mechanisms. Ther Drug Monit 1995;17:584-591.
Klintmalm GB. FK 506: an update. Clin Transplant 1994;8:207-210.
Jusko WJ, Thomson AW, Fung J, et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit 1995;17:606-614.
Dubbelboer IR, Pohanka A, Said R, et al. Quantification of tacrolimus and three demethylated metabolites in human whole blood using LC-ESI-MS/MS. Ther Drug Monit 2012;34:134-142.
Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 2007;22:328-335.
Iwasaki K, Shiraga T, Nagase K, et al. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosupresive macrolide lactone. Drug Metabolisms and Disposition 1993;21(6):971-977.
Sattler M, Guengerich FP, Yun CH, et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metabolism and Disposition 1992;20(5):753-761.
Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995;29:404-430.
Seger C, Shipkova M, Christians U, et al. Assuring the proper analytical performance of measurement procedures for immunosupresive drug concentrations in clinical practice: recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Commitee. Ther Drug Monit 2016;38:170-189.
Zahir H, McCaughan G, Gleeson M, et al. Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol 2004;57:298-309.
Ansermot N, Fathi M, Veuthey JL, et al. Quantification of cyclosporin and tacrolimus in whole blood. Comparison of liquid chromatography-electrospray mass spectrometry with the enzyme multiplied immunoassay technique. Clin Biochem 2008;41:910-913.
Tempestilli M, Di Stasio E, Basile MR, et al. Low plasma concentrations of albumin influence the affinity column-mediated immuno-assay method for the measurement of tacrolimus in blood during the early period after liver transplantation. Ther Drug Monit 2013;35:96-100.
Bazin C, Guinedor A, Barau C, et al. Evaluation of the Architect tacrolimus assay in kidney, liver, and heart transplant recipients. J Pharm Biomed Anal 2010;53:997-1002.
Wallemacq P, Goffinet JS, O’Morchoe S, et al. Multi-site analytical evaluation of the Abbott ARCHITECT tacrolimus assay. Ther Drug Monit 2009;31:198-204.
De BK, Jimenez E, De S, et al. Analytical performance characteristics of the Abbott Architect i2000 Tacrolimus assay; comparisons with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and Abbott IMx methods. Clin Chim Acta 2009;410:25-30.
Shipkova M, Vogeser M, Ramos PA, et al. Multi-center analytical evaluation of a novel automated tacrolimus immunoassay. Clin Biochem 2014;47:1069-1077.
Fung AWS, Knauer MJ, Blasutig IM, et al. Evaluation of electrochemiluminescence immunoassays for immunosuppressive drugs on the Roche cobas e411 analyzer. F1000Research 2017;6:1832.
Sasano M, Kimura S, Maeda I, et al. Analytical performance evaluation of the Elecsys(R) Cyclosporine and Elecsys(R) Tacrolimus assays on the cobas e411 analyzer. Pract Lab Med 2017;8:10-17.
Christians U, Vinks AA, Langman LJ, et al. Impact of laboratory practices on interlaboratory variability in therapeutic drug monitoring of immunosuppressive drugs. Ther Drug Monit 2015;37:718-724.
Korecka M, Shaw LM. Review of the newest HPLC methods with mass spectrometry detection for determination of immunosuppressive drugs in clinical practice. Ann Transplant 2009;14:61-72.
Zhang Y, Zhang R. Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs. Drug Test Anal 2018;10:81-94.
Storset E, Holford N, Midtvedt, et al. Importance for a tacrolimus target concentration strategy. Eur J Clin Pharmacol 2014;70:65-77.
Bergmann TK, Hennig S, Barraclough KA, et al. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. Ther Drug Monit 2014;36:62-70.
Tang JT, Andrews LM, van Gelder T, et al. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. Expert Opin Drug Metab Toxicol 2016;12:555-565.
Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002;4:813-851.
